NEW YORK (GenomeWeb News) — RNAx said today that VWR will serve as a sales representative for its RNAi services in Europe.
 
Under the multi-year, co-exclusive agreement, researchers in Europe will be able to access automated siRNA and shRNA validation services at RNAx via their local VWR specialist service representative.
 
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.